文献速递炎症性肠病

炎症性肠病中激素使用作为关键绩效指标的评估:2385例英国患者数据分析

Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-08

该研究基于英国19个中心的2385例IBD门诊患者,评估过去12个月激素暴露与激素过量/依赖情况,并分析质量改进项目与处方因素的关联。结果显示28%患者接受激素,14.8%存在激素过量或依赖;参与质量改进项目的中心激素暴露与过量均显著更低,且2015至2017年激素暴露下降。

要点

  • 28%的IBD门诊患者过去12个月接受激素,14.8%存在激素过量或依赖。
  • 参与质量改进项目的中心激素暴露与过量均显著低于非干预中心。
  • CD中抗TNF维持治疗、多学科团队和干预中心与较低激素过量相关。

核心结论

  • 该研究验证激素评估是有意义的质控指标,并为该绩效指标提供大样本基准。
  • 质量改进项目与更低的激素使用相关。

研究设计与样本

  • 研究记录19个中心IBD门诊患者的激素暴露并分析相关因素,共纳入2385例患者。
  • 同时评估为避免激素过量所采取的措施。

主要发现

  • 2385例患者中28%在过去12个月接受激素,14.8%存在激素过量或依赖。
  • 干预中心激素暴露为23.8%对31.0%(P < .001),激素过量为11.5%对17.1%(P < .001)。
  • 干预中心2015至2017年激素暴露从30.0%降至23.8%(P = .003),激素过量从13.8%降至11.5%(P = .17)。
  • 激素过量被判定为可避免者占50.7%。
  • 克罗恩病中抗TNF维持治疗OR 0.61(95%CI 0.24-0.95)、多学科团队中心OR 0.54(95%CI 0.20-0.86)、干预中心OR 0.72(95%CI 0.46-0.97)与较低激素过量独立相关;5-ASA治疗OR 1.72(95%CI 1.24-2.09)与较高激素过量相关。

临床怎么用

  • 可将激素暴露与过量/依赖作为IBD质控绩效指标进行监测。
  • 参与质量改进项目可能有助于降低激素使用。
  • CD中优先考虑抗TNF维持治疗和多学科团队管理可能减少激素过量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with IBD are at risk of excess corticosteroids. AIMS: To assess steroid excess in a large IBD cohort and test associations with quality improvement and prescribing. METHODS: Steroid exposure was recorded for outpatients attending 19 centres and associated factors analysed. Measures taken to avoid excess were assessed. RESULTS: Of 2385 patients, 28% received steroids in the preceding 12 months. 14.8% had steroid excess or dependency. Steroid use was significantly lower at 'intervention centres' which participated in a quality improvement programme (exposure: 23.8% vs 31.0%, P < .001; excess 11.5% vs 17.1%, P < .001). At intervention centres, steroid use fell from 2015 to 2017 (steroid exposure 30.0%-23.8%, P = .003; steroid excess 13.8%-11.5%, P = .17). Steroid excess was judged avoidable in 50.7%. Factors independently associated with reduced steroid excess in Crohn's disease included maintenance with anti-TNF agents (OR 0.61 [95% CI 0.24-0.95]), treatment in a centre with a multi-disciplinary team (OR 0.54 [95% CI 0.20-0.86]) and treatment at an intervention centre (OR 0.72 [95% CI 0.46-0.97]). Treatment with 5-ASA in CD was associated with higher rates of steroid excess (OR 1.72 [95% CI 1.24-2.09]). In ulcerative colitis (UC), thiopurine monotherapy was associated with steroid excess (OR 1.97 [95% CI 1.19-3.01]) and treatment at an intervention centre with less steroid excess (OR 0.72 [95% CI 0.45-0.95]). CONCLUSIONS: This study validates steroid assessment as a meaningful quality measure and provides a benchmark for this performance indicator in a large cohort. A programme of quality improvement was associated with lower steroid use.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Selinger CP, Parkes GC, Bassi A, et al. Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients. Aliment Pharmacol Ther. 2019. PMID: 31595533. doi:10.1111/apt.15497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。